{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T23:30:17Z","timestamp":1756683017276,"version":"3.32.0"},"reference-count":39,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,1,1]]},"DOI":"10.2169\/internalmedicine.3155-23","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T22:14:45Z","timestamp":1717625685000},"page":"101-107","source":"Crossref","is-referenced-by-count":3,"title":["Sustained Clinical Complete Response after Discontinuation of Trastuzumab-deruxetecan Due to Interstitial Pneumonia for HER2-positive Gastric Adenocarcinoma with Enteroblastic Differentiation (GAED)"],"prefix":"10.2169","volume":"64","author":[{"given":"Nobumi","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nariaki","family":"Odawara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gota","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rei","family":"Ishibashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Hata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Oya","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tamada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohei","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Miyakawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoku","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Shinozaki-Ushiku","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Tokyo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Ushiku","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Tokyo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"},{"name":"Department of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Murakami T, Yao T, Mitomi H, et al. Clinicopathologic and immunohistochemical characteristics of gastric adenocarcinoma with enteroblastic differentiation: a study of 29 cases. Gastric Cancer 19: 498-507, 2016.","DOI":"10.1007\/s10120-015-0497-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Murakami T, Yao T, Yatagai N, et al. Colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological study of five cases. Histopathology 76: 325-332, 2020.","DOI":"10.1111\/his.13973"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yamazawa S, Ushiku T, Shinozaki-Ushiku A, et al. Gastric cancer with primitive enterocyte phenotype: an aggressive subgroup of intestinal-type adenocarcinoma. Am J Surg Pathol 41: 989-997, 2017.","DOI":"10.1097\/PAS.0000000000000869"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kwon MJ, Byeon S, Kang SY, Kim KM. Gastric adenocarcinoma with enteroblastic differentiation should be differentiated from hepatoid adenocarcinoma: a study with emphasis on clear cells and clinicopathologic spectrum. Pathol Res Pract 215: 152525, 2019.","DOI":"10.1016\/j.prp.2019.152525"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Akazawa Y, Saito T, Hayashi T, et al. Next-generation sequencing analysis for gastric adenocarcinoma with enteroblastic differentiation: emphasis on the relationship with hepatoid adenocarcinoma. Hum Pathol 78: 79-88, 2018.","DOI":"10.1016\/j.humpath.2018.04.022"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tabernero J, Hoff PM, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol 19: 1372-1384, 2018.","DOI":"10.1016\/S1470-2045(18)30481-9"},{"key":"8","unstructured":"8. Hecht JR, Bang YJ, Qin SK, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013\/LOGiC - a randomized phase III trial. J Clin Oncol 34: 443-451, 2016."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study. Lancet Oncol 18: 640-653, 2017.","DOI":"10.1016\/S1470-2045(17)30111-0"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo) 67: 173-185, 2019.","DOI":"10.1248\/cpb.c18-00744"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 382: 2419-2430, 2020.","DOI":"10.1056\/NEJMoa2004413"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Abuhelwa Z, Alloghbi A, Alqahtani A, Nagasaka M. Trastuzumab deruxtecan-induced interstitial lung disease\/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review. Drugs 82: 979-987, 2022.","DOI":"10.1007\/s40265-022-01736-w"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Ferreira JE, Mbagwu E, Lee EY, Shelman NR, Allison DB. Cytopathological features of gastroesophageal junction adenocarcinoma with enteroblastic differentiation and histopathological correlation. Cytopathology 34: 250-253, 2023.","DOI":"10.1111\/cyt.13198"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yamabuki T, Omi M, Yonemori A, et al. Gastrointestinal obstruction due to solitary lymph node recurrence of alpha-fetoprotein-producing gastric carcinoma with enteroblastic differentiation. Case Rep Gastroenterol 8: 1-6, 2014.","DOI":"10.1159\/000358046"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nakamura Y, Matsuda K, Yokoyama S, et al. Alpha-fetoprotein-producing rectal cancer successfully responded to preoperative chemoradiotherapy: case report. Surg Case Rep 4: 111, 2018.","DOI":"10.1186\/s40792-018-0520-6"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Chen YY, Hsu WH, Hu HM, Wu DC, Lin WY. A case of alpha-fetoprotein-producing esophageal adenocarcinoma. Kaohsiung J Med Sci 29: 106-110, 2013.","DOI":"10.1016\/j.kjms.2012.08.018"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ngan RK. Outcomes of third-line trastuzumab deruxtecan in a patient with de novo stage 4 HER2-positive gastric adenocarcinoma with enteroblastic differentiation: a case report. Life (Basel) 13: 2023.","DOI":"10.3390\/life13091851"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Fujimoto M, Matsuzaki I, Nishino M, et al. HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types. J Clin Pathol 71: 600-607, 2018.","DOI":"10.1136\/jclinpath-2017-204928"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19: 1523-1529, 2008.","DOI":"10.1093\/annonc\/mdn169"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol 20: 827-836, 2019.","DOI":"10.1016\/S1470-2045(19)30088-9"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ogata T, Fujita Y, Muro K. Dramatic response to trastuzumab deruxtecan rechallenge in a patient with HER2-positive gastric cancer: a case report. Am J Case Rep 23: e935600, 2022.","DOI":"10.12659\/AJCR.935600"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Pietrantonio F, Caporale M, Morano F, et al. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research. Int J Cancer 139: 2859-2864, 2016.","DOI":"10.1002\/ijc.30408"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Saeki H, Oki E, Kashiwada T, et al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). Eur J Cancer 105: 41-49, 2018.","DOI":"10.1016\/j.ejca.2018.09.024"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kijima T, Arigami T, Uenosono Y, et al. Comparison of HER2 status before and after trastuzumab-based chemotherapy in patients with advanced gastric cancer. Anticancer Res 40: 75-80, 2020.","DOI":"10.21873\/anticanres.13927"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ignatov T, Gorbunow F, Eggemann H, Ortmann O, Ignatov A. Loss of HER2 after HER2-targeted treatment. Breast Cancer Res Treat 175: 401-408, 2019.","DOI":"10.1007\/s10549-019-05173-4"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378: 394-398, 1995.","DOI":"10.1038\/378394a0"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Hassan G, Zahra MH, Seno A, Seno M. The significance of ErbB2\/3 in the conversion of induced pluripotent stem cells into cancer stem cells. Sci Rep 12: 2711, 2022.","DOI":"10.1038\/s41598-022-04980-y"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer 26: 1-25, 2023.","DOI":"10.1007\/s10120-022-01331-8"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15: 1224-1235, 2014.","DOI":"10.1016\/S1470-2045(14)70420-6"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390: 2461-2471, 2017.","DOI":"10.1016\/S0140-6736(17)31827-5"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Wang Y, Wei X, Ke B, et al. Exploring the molecular characteristics of the malignant potential of gastric adenocarcinoma with enteroblastic differentiation. Histopathology 83: 631-646, 2023.","DOI":"10.1111\/his.14998"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Shitara K, Doi T, Dvorkin M, et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19: 1437-1448, 2018.","DOI":"10.1016\/S1470-2045(18)30739-3"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Swain SM, Nishino M, Lancaster LH, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 106: 102378, 2022.","DOI":"10.1016\/j.ctrv.2022.102378"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Powell CA, Modi S, Iwata H, et al. Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open 7: 100554, 2022.","DOI":"10.1016\/j.esmoop.2022.100554"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Rugo HS, Bianchini G, Cortes J, Henning JW, Untch M. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open 7: 100553, 2022.","DOI":"10.1016\/j.esmoop.2022.100553"},{"key":"36","unstructured":"36. Enhertu (fam-trastuzumab deruxtecan-nxki). Prescribing information. Daiichi Sankyo, 2021."},{"key":"37","unstructured":"37. Enhertu (trastuzumab deruxtecan). Summary of product characteristics. Daiichi Sankyo Europe GmbH, 2021."},{"key":"38","unstructured":"38. Enhertu (trastuzumab deruxtecan). Product monograph. Daiichi Sankyo Company, AstraZeneca Canada, 2021."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Yoshida K, Yasufuku I, Terashima M, et al. International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg 6: 227-240, 2022.","DOI":"10.1002\/ags3.12515"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/1\/64_3155-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T03:23:11Z","timestamp":1735960991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/1\/64_3155-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3155-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,1,1]]},"article-number":"3155-23"}}